Patents Assigned to Kyoto Pharmaceutical Industries, Ltd.
-
Patent number: 11267797Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 22, 2020Date of Patent: March 8, 2022Assignees: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
-
Patent number: 11013728Abstract: The present invention aims to provide a novel cyclin-dependent kinase 8 and/or 19 inhibitor useful as an anti-cancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor containing a compound represented by the formula (I): [wherein each symbol is as defined in the DESCRIPTION] or a pharmaceutically acceptable salt thereof as an active ingredient, and use thereof as an agent for preventing and/or treating cancer.Type: GrantFiled: April 2, 2018Date of Patent: May 25, 2021Assignee: Kyoto Pharmaceutical Industries, Ltd.Inventors: Tatsuya Kitao, Shigemitsu Takeda, Yoshimichi Shoji, Hiroaki Shirahase
-
Publication number: 20210100783Abstract: The present invention aims to provide a novel cyclin-dependent kinase 8 and/or 19 inhibitor useful as an anti-cancer agent. The present invention relates to a cyclin-dependent kinase 8 and/or 19 inhibitor containing a compound represented by the formula (I): [wherein each symbol is as defined in the DESCRIPTION] or a pharmaceutically acceptable salt thereof as an active ingredient, and use thereof as an agent for preventing and/or treating cancer.Type: ApplicationFiled: April 2, 2018Publication date: April 8, 2021Applicant: Kyoto Pharmaceutical Industries, Ltd.Inventors: Tatsuya KITAO, Shigemitsu TAKEDA, Yoshimichi SHOJI, Hiroaki SHIRAHASE
-
Publication number: 20200317630Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 22, 2020Publication date: October 8, 2020Applicants: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu YOSHIMURA, Masayasu KASAI, Yoshimichi SHOJI, Shigemitsu TAKEDA
-
Patent number: 10689355Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 27, 2019Date of Patent: June 23, 2020Assignees: Kyoto Pharmaceuticals Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
-
Publication number: 20190322636Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 27, 2019Publication date: October 24, 2019Applicants: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu YOSHIMURA, Masayasu KASAI, Yoshimichi SHOJI, Shigemitsu TAKEDA
-
Patent number: 10377730Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 23, 2018Date of Patent: August 13, 2019Assignees: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
-
Publication number: 20180265489Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: May 23, 2018Publication date: September 20, 2018Applicants: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu YOSHIMURA, Masayasu KASAI, Yoshimichi SHOJI, Shigemitsu TAKEDA
-
Patent number: 10059663Abstract: Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.Type: GrantFiled: August 29, 2014Date of Patent: August 28, 2018Assignee: KYOTO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Hiroaki Shirahase, Kenji Takahashi, Yoshimichi Shoji, Shigemitsu Takeda
-
Patent number: 10005752Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: GrantFiled: June 9, 2015Date of Patent: June 26, 2018Assignees: Kyoto Pharmaceutical Industries, Ltd., Sumitomo Dainippon Pharma Co., Ltd.Inventors: Yoshinobu Yoshimura, Masayasu Kasai, Yoshimichi Shoji, Shigemitsu Takeda
-
Publication number: 20170121299Abstract: The problem of the present invention is to provide a useful prodrug compound of a naphthofuran compound. The present invention relates to a compound represented by the formula (IA): [wherein each symbol is as described in the DESCRIPTION] or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 9, 2015Publication date: May 4, 2017Applicant: KYOTO PHARMACEUTICAL INDUSTRIES, LTD.Inventors: Yoshinobu YOSHIMURA, Masayasu KASAI, Yoshimichi SHOJI, Shigemitsu TAKEDA
-
Publication number: 20160207883Abstract: Provided is a compound showing a bone formation promoting action (and/or bone resorption suppressive action). A compound of the formula (I) or a pharmacologically acceptable salt: [wherein each substituent is as defined in the DESCRIPTION], has low toxicity, shows good pharmacokinetics, has an action to promote bone formation, and is useful for the prophylaxis or To treatment of metabolic bone diseases (osteoporosis, fibrous osteitis (hyperparathyroidism), osteomalacia, Paget's disease that influences the systemic bone metabolism parameter etc.) associated with a decrease in the bone formation ability as compared to the bone resorption capacity.Type: ApplicationFiled: August 29, 2014Publication date: July 21, 2016Applicant: Kyoto Pharmaceutical Industries, Ltd.Inventors: Hiroaki SHIRAHASE, Kenji TAKAHASHI, Yoshimichi SHOJI, Shigemitsu TAKEDA
-
Patent number: 7718377Abstract: The present invention provides a screening method for a compound which is highly safe and has a prophylactic or therapeutic effect on diabetes, and a highly safe pharmaceutical composition for the prophylaxis or treatment of diabetes. Specifically, a drug for the prophylaxis or treatment of diabetes, which contains, as an active ingredient, a compound having PPAR? activation activity and PTP inhibitory activity, and a method of screening for the drug are provided.Type: GrantFiled: May 28, 2004Date of Patent: May 18, 2010Assignee: Kyoto Pharmaceutical Industries, Ltd.Inventors: Kazushi Araki, Jun Ohsumi, Makoto Yachi
-
Patent number: 7557123Abstract: The novel heterocyclic compound of the present invention is a novel heterocyclic compound having the formula (I) Y: R15—C(R14)?N—O— wherein R1 is H or C1-6 alkyl, R2 is H, —CO—C(R4)?C(R4)—R5 wherein R4 is H or C1-4 alkyl, and R5 is C4-8 alkyl, C2-8 alkenyl and the like, and the like, Y is the following group wherein X is O or S, R7 is the same as R4, R8 is R10—C(R9)?C(R9)— wherein R9 is the same as R4, R10 is C3-6 alkyl and the like, and the like, R14 is the same as R4, and R15 is aryl and the like, Y—(CH2)n-O— is bonded to the 6- or 7-position of the tetrahydroisoquinoline skeleton, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: May 27, 2002Date of Patent: July 7, 2009Assignee: Kyoto Pharmaceutical Industries, Ltd.Inventors: Hiroshi Matsui, Hideo Kobayashi, Satoru Azukizawa, Masayasu Kasai, Akihisa Yoshimi, Hiroaki Shirahase
-
Patent number: 7429612Abstract: The present invention provides an indoline compound represented by the formula (I) wherein each symbol is as defined in the DESCRIPTION, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing this indoline compound or a pharmaceutically acceptable salt thereof. The compound of the present invention shows superior ACAT inhibitory effect and superior lipoperoxidation inhibitory effect and is useful as an ACAT inhibitor or a lipoperoxidation inhibitor.Type: GrantFiled: July 16, 2003Date of Patent: September 30, 2008Assignee: Kyoto Pharmaceutical Industries, Ltd.Inventors: Shouji Kamiya, Miho Ikai, Kenji Takahash, Tadatsugu Tarumi, Masayasu Kasai, Akihisa Yoshimi, Hiroaki Shirahase
-
Patent number: 6872732Abstract: The novel heterocyclic derivative of the present invention is a novel heterocyclic derivative having the formula (I?) wherein R1 is a hydrogen atom or C1-6 alkyl, R2 is —CO—C(R4)?C(R4)—R5 wherein R4 is a hydrogen atom or C1-4 alkyl, and R5 is C4-8 alkyl, C2-8 alkenyl, aryl or aromatic heterocycle, —CO—C?C—R6 wherein R6 is C1-8 alkyl and the like, R3 is a hydrogen atom or C1-4 alkyl, X is an oxygen atom or a sulfur atom, R20 is optionally substituted phenyl, and n is an integer of 1 to 4, or a pharmaceutically acceptable salt thereof. The compound (I?) of the present invention is useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complications, a glucose tolerance improver, an anti-arteriosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated diseases and an agent for the prophylaxis or treatment of syndrome X.Type: GrantFiled: May 27, 2002Date of Patent: March 29, 2005Assignee: Kyoto Pharmaceutical Industries, Ltd.Inventors: Hiroshi Matsui, Hideo Kobayashi, Satoru Azukizawa, Masayasu Kasai, Akihisa Yoshimi, Hiroaki Shirahase
-
Patent number: 6630473Abstract: The present invention provides an anti-inflammatory medicament and an inhibitor of intraocular pressure rise due to laser irradiation, which contains 1,4-dihydropyridine derivative of the formula (I) wherein X1 and X2 are the same or different and each is hydrogen atom, fluoromethyl, fluoromethoxy, halogen, cyano or nitro, R1 is lower alkyl, R2 is acyl, alkoxycarbonyl, acylalkyl, N-alkyl-substituted carbamoylalkyl, alkoxyalkyl, alkoxycarbonylalkyl, acyloxyalkyl, nitratoalkyl, cyanoalkyl, hetero ring-alkyl, haloalkyl, alkenyl or alkynyl, A is alkylene having a carbon atom bonded with two alkyls and 5 or more carbon atoms in total, and m is an integer of 1 to 3, or an acid addition salt thereof, as an active ingredient.Type: GrantFiled: October 10, 2001Date of Patent: October 7, 2003Assignees: Senju Pharmaceutical Co., Ltd., Kyoto Pharmaceutical Industries, Ltd.Inventor: Mitsunori Waki
-
Patent number: 6589963Abstract: A heterocyclic compound of the formula [I] wherein R1 is hydrogen atom or lower alkyl, R2 is hydrogen atom, alkyl optionally having a substituent and the like, R3 is hydrogen atom, lower alkyl and the like, A is a single bond or >N—R5 wherein R5 is hydrogen atom or lower alkyl, B is lower alkylene, and Y is aryl optionally having a substituent and the like, and a pharmaceutically acceptable salt thereof show a hypoglycemic action, a blood hypolipidemic action, an insulin resistance-improving action and a PPAR activating action, and are useful as a hypoglycemic agent, a hypolipidemic agent, an insulin resistance improver, a therapeutic agent of diabetes, a therapeutic agent of diabetic complication, a glucose tolerance improver, an anti-atherosclerosis agent, an anti-obesity agent, an antiinflammatory agent, an agent for the prophylaxis or treatment of PPAR-mediated disease and an agent for the prophylaxis or treatment of syndrome X.Type: GrantFiled: May 31, 2002Date of Patent: July 8, 2003Assignee: Kyoto Pharmaceutical Industries, Ltd.Inventors: Hiroshi Matsui, Hideo Kobayashi, Satoru Azukizawa, Masayasu Kasai, Akihisa Yoshimi, Hiroaki Shirahase
-
Patent number: 6451799Abstract: An agent for ameliorating ocular circulatory disorder containing a 1,4-dihydropyridine derivative of the formula (I) wherein each symbol is as defined in the specification, or an acid addition salt thereof as an active ingredient. The agent for ameliorating ocular circulatory disorder containing the compound of the above formula (I) increases optic disc blood flow of normal eye particularly by instillation, and inhibits vasocontraction of retinal blood vessel, decrease in optic disc blood flow and attenuation of the amplitude of VEP caused by ET-1, without increasing the intraocular pressure.Type: GrantFiled: April 27, 1999Date of Patent: September 17, 2002Assignees: Senju Pharmaceutical Co., Ltd., Kyoto Pharmaceutical Industries, Ltd.Inventors: Takahiro Ogawa, Noriko Watanabe, Mitsunori Waki
-
Patent number: RE38970Abstract: A heterocyclic derivative of the formula (I) wherein each symbol is as defined in the specification, and pharmaceutically acceptable salts thereof. The compound (I) of the present invention and pharmaceutically acceptable salts thereof exhibit superior ACAT inhibitory activity and lipoperoxidation inhibitory activity in mammals, and are useful as ACAT inhibitors and lipoperoxidation inhibitors. Specifically, they are useful for the prophylaxis and treatment of arteriosclerosis, hyperlipemia, arteriosclerosis in diabetes, and cerebrovascular and cardiovascular ischemic diseases.Type: GrantFiled: September 30, 1996Date of Patent: February 7, 2006Assignee: Kyoto Pharmaceutical Industries, Ltd.Inventors: Shoji Kamiya, Hiroaki Shirahase, Hiroshi Matsui, Shohei Nakamura, Katsuo Wada